Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.70 |
| ▸ | MME | P08473 | 1/20 | 0.66 |
| ▸ | ACE | P12821 | 1/20 | 0.66 |
| ▸ | CPA1 | P15085 | 1/20 | 0.66 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.66 |
| ▸ | GPR34 | Q9UPC5 | 6/20 | 0.65 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.61 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | MMP8 | P22894 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16541078 | 1.00 | PPARG (0.70) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL16552342 | 0.91 | PPARG (0.69) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL19364838 | 0.91 | PPARG (0.62) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL9161282 | 0.90 | ITGB3 (0.75) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL14338208 | 0.90 | ITGB3 (0.75) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL1023326 | 0.90 | ITGB3 (0.75) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL27703721 | 0.90 | ITGB3 (0.75) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL888747 | 0.89 | NPC1 (0.59) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL10122834 | 0.89 | NPC1 (0.59) | PPARGMMEACECPA1ACE2 | |
| SCHEMBL2747735 | 0.88 | PPARG (0.65) | PPARGMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3039009-B1 | MAO-B SELECTIVE INHIBITOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF | UNIV BRITISH COLUMBIA (CA) | 2019-05-01 | — | — | EP | disclosed |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2019-02-05 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-09 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-7659270-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-17 | — | — | US | disclosed |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-18 | — | — | US | disclosed |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-12-04 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | PPARG 2209/4885MME 1155/4885ACE 805/4885 |
| US-10196345-B2 | MAO-B selective inhibitor compounds, pharmaceutical compositions thereof and uses thereof | MAOB, MAOA, COMT | PPARG 1707/4885MME 785/4885ACE 765/4885 |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20090233925-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20080299075-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20080044379-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20170320833-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20090202483-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20080044380-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
| US-20080311075-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | PPARG 1898/4885MME 1382/4885ACE 865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.